India’s medical technology sector is set to receive its first dedicated investment fund, with MedArtha Capital planning to raise ₹1,000 crore to back growth‑stage device makers and boost domestic manufacturing. The sector-specific fund aims to support Indian medtech companies that has established products but need capital and operational support to scale, aligning with the broader push to reduce dependence on imported devices and strengthen the local healthcare ecosystem.
The alternative investment fund has received market regulator approval and will be led by industry professionals with experience in medical devices and healthcare. It is expected to focus on companies that are already generating meaningful revenue, with investments intended to help them expand manufacturing capacity, deepen market reach and build stronger development and innovation capabilities. The initiative is being positioned as a catalyst for accelerating the growth of Indian-made medical technologies, particularly in segments where demand is rising but domestic players remain underrepresented.
The move comes at a time when India is trying to build a more resilient health infrastructure and encourage greater self-reliance in critical medical technologies. A dedicated medtech fund of this scale is expected to draw more attention to the sector from institutional and strategic investors, potentially improving access to capital for device makers that have traditionally struggled to compete with larger global players. If executed as planned, the fund could help bridge key gaps in funding and scale, and contribute to making advanced medical devices more accessible within the country.
